ArticleClinical oral investigations2022
Is periodontal inflamed surface area associated with serum and salivary levels of IL-1β, visfatin, and omentin-1 in overweight/obese patients?
Article in Clinical oral investigations, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.
- Pooled it
- Correlation between periodontal status, whole salivary interleukin-1beta levels and oral yeasts carriage among individuals with varying ranges of body mass index.Acta odontologica Scandinavica · 2025Article
- Omentin-1 mitigates non-alcoholic fatty liver disease by preserving autophagy through AMPKα/mTOR signaling pathway.Scientific reports · 2024Article
- Article
- Retinol-Binding Protein 4 and Visfatin Levels in Patients with Periodontitis and Obesity/Overweight: A Systematic Review and Meta-Analysis.Current issues in molecular biology · 2023Review
- Inflammatory profile of patients with different weight diagnoses and similar periodontal condition: A systematic review.Journal of Indian Society of PeriodontologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
objectivesThe aim of this study was to evaluate the levels of salivary and serum interleukin (IL)-1β, visfatin, and omentin-1 in the relationship between periodontal disease and overweight/obesity as well as to reveal the possible role of periodontal inflamed surface area (PISA) in this association. MATERIALS AND
methodsNinety-six individuals (69 females, 27 males) were divided into 4 groups as systemically healthy (H) and non-periodontitis (HnP, n = 23), systemically healthy and periodontitis (HP, n = 24), overweight/obese (O) and non-periodontitis (OnP, n = 25), and overweight/obese and periodontitis (OP, n = 24). Periodontal parameters were measured, and PISA was calculated. IL-1β, visfatin, and omentin-1 levels in saliva and serum samples were analysed.
resultsPeriodontal parameters deteriorated, salivary and serum IL-1β and visfatin levels were increased, and omentin-1 levels were decreased in OnP and OP groups, compared to HnP and HP groups. Salivary and serum IL-1β and visfatin levels were increased and omentin-1 levels were decreased in periodontitis groups, compared to HnP and OnP groups. PISA was negatively correlated with salivary omentin-1 and positively correlated with salivary and serum visfatin in H and O groups, whereas a positive relationship was found between PISA and salivary and serum IL-1β in H group.
conclusionsPISA may be negatively associated with salivary omentin-1, while positively correlated with salivary and serum visfatin in overweight/obese patients. CLINICAL RELEVANCE: Co-evaluation of PISA and adipokines seems to be an innovative approach to evaluate the association between periodontitis and overweight/obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.